MAPT and Alzheimer disease: Taking into account that an AD diagnosis in a clinical setting of progressive cognitive decline requires demonstration of either amyloid and tau pathology or amyloid and tau biomarkers, the researchers concluded that most cases do not fulfill the necessary criteria for AD diagnosis according to well-established clinical and pathological standards.